Frequency of LRP4 antibodies in a consecutive cohort of suspected Myasthenia Gravis patients.
/0 Commenti/in GRUPPO 3, musumeci, nigro, Uncategorized/da expomeetingThe DMD Hub Central Recruitment Database, a model for effective recruitment to Rare Disease clinical trials
/0 Commenti/in GRUPPO 3, musumeci, nigro, Uncategorized/da expomeetingNovel biomarkers for limb-girdle muscular dystrophy associated to CAPN3 mutation
/0 Commenti/in GRUPPO 3, musumeci, nigro, Uncategorized/da expomeetingEFFECTIVENESS OF THYMECTOMY IN JUVENILE MYASTHENIA GRAVIS: PRELIMINARY RESULTS OF A15-YEAR FOLLOW UP STUDY
/0 Commenti/in GRUPPO 3, musumeci, nigro, Uncategorized/da expomeetingA familiar case of ptosis and dysphagia with facial dysmofisms due to a novel KMT2D gene mutation.
/0 Commenti/in GRUPPO 3, musumeci, nigro, Uncategorized/da expomeetingPROGRESSIVE MYOPATHY AND POLYNEUROPATHY
/0 Commenti/in GRUPPO 3, musumeci, nigro, Uncategorized/da expomeetingSUBACUTE ATAXIC SENSITIVE SYNDROME
/0 Commenti/in GRUPPO 3, musumeci, nigro, Uncategorized/da expomeetingSLEEPY PATIENTS WITH MYOTHONIC DYSTROPHY TIPE 1 DO NOT HAVE A DISTINCT NEUROPSYCHOLOGICAL AND NEUROIMAGING PATTERN COMPARED TO NON SLEEPY PATIENTS
/0 Commenti/in GRUPPO 3, musumeci, nigro, Uncategorized/da expomeetingClinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post Hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study
/0 Commenti/in GRUPPO 3, musumeci, nigro, Uncategorized/da expomeetingSEGRETERIA NAZIONALE AIM
Seguici sulle nostre pagine social
SEGRETERIA ORGANIZZATIVA FIRST CLASS
First Class S.r.l. Meetings and Conferences